JPMorgan: Overweight rating on Agricultural Bank of China (01288), target price HK$7.35
JPMorgan expects Agricultural Bank of China's earnings per share to grow by 5.9%, 5.2%, and 5.4% in 2026, 2027, and 2028, respectively.
JPMorgan released a research report stating that after the restriction period ended, it adjusted its rating on Agricultural Bank of China (01288) from "Not Rated" to "Overweight" and gave a target price of HK$7.35. The bank expects Agricultural Bank of China's earnings per share to grow by 5.9%, 5.2%, and 5.4% in 2026, 2027, and 2028, respectively.
JPMorgan pointed out that Agricultural Bank of China's asset quality has improved, and its non-performing loan provision coverage ratio is the highest among the four major mainland banks, providing more buffer space for future earnings. In addition, the bank has relatively low overseas exposure and is less affected by recession risks in overseas markets. However, Agricultural Bank of China's core tier-1 capital adequacy ratio is relatively low, and its risk-weighted asset growth is relatively high.
Related Articles

Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.
MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.

KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.
Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.

MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.
KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.






